Athanasios Pallis

Merck (Germany) — Germany

Medicine · Health Sciences

34h-index3.6kcitations151works3.62yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(49), Colorectal Cancer Treatments and Studies(30), Lung Cancer Research Studies(22), Cancer Treatment and Pharmacology(19), Lung Cancer Diagnosis and Treatment(18)

Publications151 total

962P Precemtabart tocentecan (M9140), an anti-CEACAM5 ADC with exatecan payload, in patients with metastatic colorectal cancer: Updated clinical data from the phase I PROCEADE-CRC-01 study
Annals of Oncology·2025
Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial
Nature Medicine·2025· 10 citedOpen Access
Precemtabart tocentecan (M9140), an anti-CEACAM5 ADC with exatecan payload, in patients with metastatic colorectal cancer (mCRC): Results from the dose optimization of the phase 1 PROCEADE CRC-01 study.
Journal of Clinical Oncology·2025· 2 cited
PROCEADE PanTumor: A phase 1b/2, multicenter study of precemtabart tocentecan (M9140), an anti-CEACAM5 antibody-drug conjugate (ADC) with exatecan payload, in patients with advanced solid tumors.
Journal of Clinical Oncology·2025
Abstract CT117: PROCEADE PanTumor: A Phase 1b/2, multicenter study of precemtabart tocentecan (M9140), an anti-CEACAM5 antibody-drug conjugate (ADC) with exatecan payload, in patients with advanced solid tumors
Cancer Research·2025
573P M9140, an anti-CEACAM5 antibody drug conjugate (ADC), in patients with metastatic colorectal cancer (mCRC): Updated results from a phase I trial
Annals of Oncology·2024· 2 citedOpen Access
First-in-human trial of M9140, an anti-CEACAM5 antibody drug conjugate (ADC) with exatecan payload, in patients (pts) with metastatic colorectal cancer (mCRC).
Journal of Clinical Oncology·2024· 11 cited
Interoceanic passages
2021
Port–city relationships
2021
Digital transformation
2021· 8 cited
Epilog
2021
Break bulk
2021
Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B‐cell non‐Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306)
British Journal of Haematology·2019· 18 citedOpen Access
A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer
Cancer Chemotherapy and Pharmacology·2019· 18 citedOpen Access
Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Blood·2018· 39 cited
Abstract P1-09-11: A phase Ib study of oral administration of lucitanib in combination with fulvestrant in patients with HR+ metastatic breast cancer (mBC)
Cancer Research·2018
Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors
Clinical & Translational Oncology·2017· 3 cited
Medical treatment of lung cancer (neo and adjuvant chemoradiotherapy)
Cambridge University Press eBooks·2016
Biweekly Carboplatin Plus Gemcitabine as First-Line Treatment of Elderly Patients With Advanced Squamous Non–Small-cell Lung Cancer: A Multicenter Phase I-II Trial by the Hellenic Oncology Research Group
Clinical Lung Cancer·2016· 10 cited
Abstract OT1-03-03: FINESSE - An open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or non-amplIfied oestrogeN rEceptor poSitive metaStatic breast cancEr
Cancer Research·2016· 5 cited
page 1 of 8Next →

Frequent Co-authors

Sofia Agelaki(10), Vassilis Georgoulias(8), D. Mavroudis(7), Vassilis Georgoulias(7), Ulrich Wedding(6), John Souglakos(6), Kostas Kalbakis(6), Cesare Gridelli(5), Stella Apostolaki(5), Maria Perraki(5), Athina Agelidou(5), Hans Wildiers(4), Jan P. van Meerbeeck(4), Ioannis G. Vlachonikolis(4), Ioannis Mouzas(4), Αthanasios Kotsakis(4), Stylianos Kakolyris(4), V. Georgoulias(4), Dimitris Mavroudis(4), Ioannis Varthalitis(4)